Navigation Links
Radionuclide treatment against small tumors and metastases

This release is available in German.

A cancer diagnosis is not necessarily a death sentence. There are now quite a number of possibilities to treat cancer. In addition to radiotherapy and chemotherapy, so-called radionuclide treatment has also become an important component in the fight against the mutated cells. It involves injecting radioactive elements, so-called nuclides, into the patient's circulatory system. Bonded to special molecules which preferentially attach themselves to cancer cells, the nuclides are pumped through the body by the heart until they finally find their target: a cancer cell. Having arrived there, they attach themselves to its cell walls, decay and thus release radiation into their surroundings. This attacks the cancer cells at close range and ideally destroys them.

Lutetium-177 is a nuclide already used for clinical applications. As it decays, fast electrons, so-called beta particles, are generated. In human tissue they have a range of up to 100 micrometers, five times the diameter of a tumor cell. They can therefore also damage healthy tissue in the vicinity. Dr. Silvia Lehenberger, a radiochemist at the TUM, has now succeeded in producing the Terbium-161 nuclide pure enough and in quantities sufficient for therapeutic applications. The nuclide emits not only the beta particles, but also conversion and Auger electrons, which have a range of only 0.5 to 30 micrometers. Their ranges match the size of tumor cells, making them ideal for the treatment of small tumors and metastases. "Moreover, the nuclide has a higher energy content than comparable particles," explains Silvia Lehenberger. "This means smaller doses can be administered to the patient, which in turn means a reduction in the radiation exposure."

Like lutetium or neodymium, which is familiar from high-power magnets, terbium is one of the so-called rare earth metals. The elements of the rare earths are extremely similar in chemical terms. Moreover, the raw material contains impurities which would not be permissible for a clinical application. It was therefore essential to develop suitable separation methods in order to be able to isolate the desired terbium-161 in as pure a state as possible. Coauthor and TUM colleague Christoph Barkhausen played a crucial role in the development of the separation method. The similarity of the rare earth elements also has an advantage, however: The medical application worked out for Lutetium-177 can also be used for Terbium-161.

A cooperation between Silvia Lehenberger and researchers at the Paul Scherrer Institute in Villingen (Switzerland) has already been able to prove the effectiveness of the nuclide on cancer cells in the laboratory. This is only the first step on the road to the final medication, however. It must pass a great many tests before it can be administered to people in hospital.

The researchers produced the Terbium-161 nuclide from Gadolinium-160 by neutron irradiation at the Garching FRM II research neutron source. Terbium-161 is ideal for therapeutic purposes because it has a half-life of only 6.9 days. This has the advantage that, after it has been produced, it can be transported to the clinic where it is to be used without losing much of its activity; it also means that the radiation has already decayed to about one percent of its original value after 50 days.

The work was undertaken as part of a cooperation between Radiochemistry Munich (RCM) at the TUM and the Laboratory for Radiochemistry and Environmental Chemistry and the Center for Radiopharmaceutical Sciences at the Paul Scherrer Institute (Villingen/Switzerland). The Terbium-161 was mainly produced at the neutron source of the Technische Universitaet Muenchen in Garching and additionally at the Institut Laue-Langevin in Grenoble and in the neutron source of the Helmholtz Center Berlin. Lutetium-177 for comparative tests was provided by Isotope Technologies Garching GmbH, which has been providing this nuclide to hospitals for many years for therapeutic purposes.


Contact: Dr. Andreas Battenberg
Technische Universitaet Muenchen

Related medicine news :

1. Treatment gap leaves many older adults at unnecessary risk of fracture
2. Cooling the brain during sleep may be a natural and effective treatment for insomnia
3. Certain head and neck cancer patients benefit from second round of treatment
4. Treatment for Abuse of Anti-Anxiety Drugs Tripled Over 10 Years
5. Coffee drinking improves hepatitis C treatment response
6. Many patients with advanced cancers get treatments that wont help
7. Surgically shrinking the stomach when conservative weight-loss treatments fail
8. Calorie-burning brown fat is a potential obesity treatment, researchers say
9. Flaxseed Fails as Treatment for Hot Flashes
10. Stem cell treatment may offer option for broken bones that dont heal
11. Anorexic girls have increased bone density after physiological estrogen treatment
Post Your Comments:
Related Image:
Radionuclide treatment against small tumors and metastases
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced ... Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a ... including their ability to work and be productive, to do simple daily activities like ...
(Date:12/1/2015)... ... December 02, 2015 , ... ClinicoEconomics and Outcomes Research ... of treatment for osteoporosis ”. , As corresponding author Dr Ankita Modi says ... with osteoporosis. Based on a large US managed care database, women aged 55 ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... named by MedEsthetics magazine as the Best Single Physician Practice in the nation. Dr. ... elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said he ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  InCarda Therapeutics, ... development and commercialization of therapies for cardiovascular conditions via ... a subsidiary business in Australia . ... trial in Australia in the ... leading investigators and medical centers in Adelaide ...
(Date:12/1/2015)... , Dec. 1, 2015  The migration ... to develop shared care plans that help patients ... care plans will be digitally enabled, incorporate care ... needs and desires. They will also allow all ... patient,s health journey is optimal. That is the ...
Breaking Medicine Technology: